New Domestic Drugs Target China
New Domestic Drugs Target China
  • 고현석 선임기자
  • admin@hkn24.com
  • 승인 2013.01.31 14:47
  • 댓글 0
이 기사를 공유합니다

[SEOUL=Healthkoreanews]  Domestic drugs developed by Korean pharmaceutical companies are targeting China.

Donga Pharm's 'Motilitone', Ahngook Pharm's 'Synatura', JW Holdings' 'Curan' and Boryung Pharm's 'Kanarb'
are on the front. JW Holdings signed an export contract with Chinese Green Pine (TIANJIN) Pharma over Q-ROXIN,fluoroquinolone antibiotics, also the 4th domestically-developed new drug.

JW Holdings is expected to supply Q-ROXIN to Green Pine Pharma for the next 5 years from year 2016
after the completion of registering process with Chinese FDA. 

JW Holdings has been recording over seven million dollars in Chinese market on a yearly basis since 2006 through the export of next-generation antibiotics, Prepenem. With the export contract of Curan following Combiflex Lipid, three-chamber parenteral nutritional lipid bag in 2009, the firm's attack on Chinese market is expected to be fiercer.

Donga Pharm has also advanced to the front line with Motilitone, new natural dru.
Motilitone, gastrointestinal treatment, was released Jan 2012 and has since recorded the prescription of 13.2 billion won, getting listed as a blockbuster drug.

Donga Pharm, with this national hit, is also full-fledgedly preparing for 'Attack on China' plan through applying for bridge clinical trial with Chinese Clinical Phase I.

The entry of Monilitone into Chinese market is progressing as part of Ministry of Knowledge Economy's global natural drug promoting research project.

Donga Pharm is also arranging for clinical trial application(IND) for the purpose of entry of new drug 'DA-1229', diabetes treatment through the out-licensing contract with Chinese Luye Pharma in Feb 2012. 

Ahngook Pharm has kicked into high gear for Chinese entry with 'Synatura', new botanical drug approved in South Korea to treat acute respiratory infection and chronic inflammatory bronchitis.Synatura, released in Sep 2011, has entered into blockbuster drug list. The total sales of Synatura last year reached 34.5 billion won.

Synatura applied August 2012 for Chinese Clinical Phase III after being approved as Ministry of Knowledge Economy's Task. Ahngook Pharm, with the reinforcement of marketing of 'G-Scanning Service' in cooperation with MicroGen, started last September, in Chinese market, is expecting the expansion of Synatura market through Beijing Office. 

Kanarb, a new ARB medicine for high blood pressure developed by Boryung Pharm, is currently under negotiation for export contract with a multinational pharmaceutical company stationed in China. The contact is expected to finally materialize within first quarter of this year.

Green Cross corp is also expanding its global business through establishing Anhui Green Cross Pharmaceuticals, Chinese wholesale subsidiary last year, though not an explicit entry into Chinese market.  

According to Korea Pharmaceutical Traders Association, the size of Chinese drug market is about 166 trillion won as of year 2012, showing approximately average 15% yearly growth for the last three years. Since the demand of generic drugs among prescription drugs occupies more than 90%, the market is considered as blue ocean for domestic drug companies which has a large amount of generic drug lines. Domestic drug makers agree that stepping stones for Chinese entry be prepared. Though the entry itself is a tough task, if landed successfully, future performance is guaranteed, analyze domestic drug makers.  

An official from domestic pharmaceutical companies said, "In the past, the challenge took so long. But the potential is so huge that domestic drug makers should make use of elaborate and strategic approach. For the successful entry into Chinese market, localization strategy and government support is pivotal."
He added, "Entry into Chinese market by domestic drug makers armed with competitive edge in generic drug production will be the short cut to globalization of the firms." 

-대한민국 의학전문지 헬스코리아뉴스-


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

      • 회사명 : (주)헬코미디어
      • 서울특별시 마포구 매봉산로2길 45, 302호(상암동, 해나리빌딩)
      • 대표전화 : 02-364-2002
      • 청소년보호책임자 : 이슬기
      • 제호 : 헬스코리아뉴스
      • 발행일 : 2007-01-01
      • 등록번호 : 서울 아 00717
      • 재등록일 : 2008-11-27
      • 발행인 : 임도이
      • 편집인 : 이순호
      • 헬스코리아뉴스에서 발행하는 모든 저작물(컨텐츠, 기사)는 저작권법의 보호를 받는 바, 무단·전재·복제·배포 등을 금합니다.
      • 「열린보도원칙」 당 매체는 독자와 취재원 등 뉴스이용자의 권리 보장을 위해 반론이나 정정보도, 추후보도를 요청할 수 있는 창구를 열어두고
        있음을 알려드립니다. 고충처리인 이슬기 02-364-2002 webmaster@hkn24.com
      • Copyright © 2024 헬스코리아뉴스. All rights reserved. mail to admin@hkn24.com
      ND소프트
      편집자 추천 뉴스
      베스트 클릭